Last reviewed · How we verify
ULSC
At a glance
| Generic name | ULSC |
|---|---|
| Sponsor | Restem, LLC. |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Safety and Efficacy of ULSC on Disease Severity and Steroid Tapering in Participants With Dermatomyositis/ Polymyositis (DM/PM), Also Known as Idiopathic Inflammatory Myopathy (IIM) (PHASE2, PHASE3)
- Safety and Preliminary Efficacy of ULSC in Facioscapulohumeral Muscular Dystrophy (FSHD) (PHASE1)
- Phase 1 Study of ULSC in Patients With Polymyositis (PM) and Dermatomyositis (DM) (EARLY_PHASE1)
- Umbilical Cord Lining Stem Cells (ULSC) in Patients With COVID-19 ARDS (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ULSC CI brief — competitive landscape report
- ULSC updates RSS · CI watch RSS
- Restem, LLC. portfolio CI